NOVARTIND · NSE
Not in active coverage. Cited reporting has mentioned Novartis India, the record of those mentions is below. Your interest is logged; coverage expands by demand.
Novartis India shares surged 18 per cent in Thursday's trade, extending its recent rally to ninth straight session.
Novartis India's board approved the acquisition of the 'Minipress' and 'Minipres' trademarks from Pfizer Inc, USA, and Pfizer Products Inc, USA, for approximately Rs 1,250 crore.
Novartis India Ltd surged 20.00% to Rs 2188 on September 09, 2026, making it the biggest gainer in the BSE's 'B' group.
Shares of Novartis India extended their gains for the eighth consecutive day and were locked in a 20% upper circuit to hit a fresh record high of ₹2,186.40 apiece on Wednesday, September 9.
Novartis India entered into an exclusive promotion and distribution agreement with Novartis Healthcare Private Limited for the promotion and distribution of NHPL's retina portfolio comprising the products Accentrix and Pagenax in the Indian market.
Novartis India has entered into an Exclusive Promotion and Distribution Agreement with Novartis Healthcare for the distribution of Accentrix (ranibizumab) and Pagenax (brolucizumab) in India.
Novartis India will acquire the Minipress and Minipres trademarks and related intellectual property from Pfizer for about ₹1,250 crore.
Novartis India announced the acquisition of the Minipress and Minipres trademarks in India and certain related intellectual property rights from Pfizer Inc and Pfizer Products Inc USA for an aggregate consideration of Rs 1,250 crore.
Novartis India Ltd plans to pursue disciplined, therapy-aligned acquisitions and deepen its last-mile reach into Tier 2 and Tier 3 markets to drive its next phase of growth.
This page lists where cited reporting has mentioned Novartis India. It is not the full dossier: developments here are single mentions, not corroborated records. We compile and cite; we do not opine.
New here? The reader's guide explains every page, plate by plate.
fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.